Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

But Repare and Black Diamond still have rebuilding to do.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.

AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.

Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.